Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.9070
+0.0690 (8.23%)
At close: Aug 13, 2025, 4:00 PM
0.9200
+0.0130 (1.43%)
Pre-market: Aug 14, 2025, 8:02 AM EDT
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $51.21 million as of August 14, 2025. Its market cap has decreased by -82.89% in one year.
Market Cap
51.21M
Enterprise Value
-29.94M
1-Year Change
-82.89%
Ranking
Category
Stock Price
$0.91
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $51.21M, a decrease of -93.65%. That is a compound annual growth rate of -43.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2025 | 51.21M | -27.02% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 592.95B |
| Johnson & Johnson | 420.06B |
| AbbVie | 355.91B |
| UnitedHealth Group | 246.17B |
| AstraZeneca | 240.81B |
| Novartis AG | 234.72B |
| Novo Nordisk | 227.37B |
| Abbott Laboratories | 225.22B |